<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5188">
  <stage>Registered</stage>
  <submitdate>6/10/2015</submitdate>
  <approvaldate>6/10/2015</approvaldate>
  <nctid>NCT02569801</nctid>
  <trial_identification>
    <studytitle>A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy</studytitle>
    <scientifictitle>A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy</scientifictitle>
    <utrn />
    <trialacronym>HydranGea</trialacronym>
    <secondaryid>2015-000106-19</secondaryid>
    <secondaryid>GO29689</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fulvestrant
Treatment: drugs - GDC-0810

Active Comparator: Fulvestrant - Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.

Experimental: GDC-0810 - Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.


Treatment: drugs: Fulvestrant
Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.

Treatment: drugs: GDC-0810
GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intent-to-Treat (ITT) Population</outcome>
      <timepoint>From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 25 months)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PFS According to RECIST v1.1 in Participants With Estrogen Receptor (ESR)1 Mutations</outcome>
      <timepoint>From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 25 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>From Day 1 to death from any cause, assessed up to end of study (up to approximately 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Objective Response (Partial Response [PR] Plus Complete Response [CR]) According to RECIST v1.1</outcome>
      <timepoint>From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DOR) Assessed Using RECIST v1.1</outcome>
      <timepoint>From objective response to PD or death from any cause, assessed up to end of study (up to approximately 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Clinical Benefit (PR, CR, or Stable Disease, Lasting for At Least 24 Weeks) Assessed Using RECIST v1.1</outcome>
      <timepoint>From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)</outcome>
      <timepoint>From Day 1 to 28 days after last dose of study drug, assessed up to end of study (up to approximately 25 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent Oral Clearance (CL/F) of GDC-0810</outcome>
      <timepoint>Predose (within 30 minutes of GDC-0810 administration) and 3 hours postdose on Day 1 of Cycles 1 and 3; Cycle length=28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent Volume of Distribution (Vz/F) of GDC-0810</outcome>
      <timepoint>Predose (within 30 minutes of GDC-0810 administration) and 3 hours postdose on Day 1 of Cycles 1 and 3; Cycle length=28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absorption Rate Constant (Ka) of GDC-0810</outcome>
      <timepoint>Predose (within 30 minutes of GDC-0810 administration) and 3 hours postdose on Day 1 of Cycles 1 and 3; Cycle length=28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Postmenopausal women with histologically or cytologically confirmed invasive, ER+/HER-
             (defined by local guidelines) metastatic or inoperable, locally advance breast cancer

          -  Participants for whom endocrine therapy is recommended and treatment with cytotoxic
             chemotherapy is not indicated at time of entry into the study

          -  Participants must have measurable disease by RECIST v1.1 or non-measurable, evaluable
             disease with atleast one evaluable bone lesion by RECIST v1.1 based on radiologic
             scans within 28 days of Day 1 of Cycle 1

          -  Participants with radiologic/objective evidence of breast cancer recurrence or
             progression while on or within 6 months after the end of adjuvant treatment with an
             AI, or progression while on or within 1 month after the end of prior AI treatment for
             locally advanced or metastatic breast cancer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  HER2-positive disease

          -  Prior treatment with fulvestrant

          -  Prior treatment with greater than (&gt;) 1 cytotoxic chemotherapy regimen or &gt;2 endocrine
             therapies for advanced or metastatic disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>6/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>71</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>4/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,TAS,VIC</recruitmentstate>
    <hospital>St Vincent's Hospital Sydney - Darlinghurst</hospital>
    <hospital>Port Macquarie Base Hospital - Port Macquarie</hospital>
    <hospital>Adelaide Cancer Centre - Kurralta Park</hospital>
    <hospital>Royal Hobart Hospital; Medical Oncology - Hobart</hospital>
    <hospital>Footscray Hospital - Footscray</hospital>
    <hospital>Peninsula and South Eastern Haematology and Oncology Grou - Frankston</hospital>
    <hospital>Peter Maccallum Cancer Centre - Melbourne</hospital>
    <hospital>Epworth HealthCare; Clinical Trials Centre - Richmond</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3121 - Richmond</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koblenz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Krefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Witten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Ulsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coru√±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Lerida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Macclesfield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of
      GDC-0810 compared with fulvestrant in postmenopausal women with advanced or metastatic
      estrogen receptor positive (ER+)/ human epidermal growth factor receptor 2 negative (HER2-)
      breast cancer resistant to AI therapy. The development of GDC-0810 has been halted by the
      Sponsor and the enrollment in this study has been discontinued. Participants currently
      enrolled in the study who are experiencing clinical benefit may continue receiving GDC-0810
      as a single agent or fulvestrant until disease progression (PD), unmanageable toxicity,
      withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of the study by the
      Sponsor.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02569801</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>